VS
iShares Genomics Immunology and Healthcare Index ETF (XDNA) and First Trust NYSE Arca Biotechnology ETF (FBT) offer distinct profiles for Canadian ETF investors. A direct comparison shows that XDNA focuses its top 3 sector exposures on Healthcare, while FBT leans towards Healthcare. When evaluating costs, XDNA features a management fee (MER) of 0.39%, compared to 0.15% for FBT. Performance-wise, XDNA has returned 50.65% year-to-date with +$6 M in net flows, whereas FBT is at 29.08% with +$4 M. Use the comparison tool below to benchmark these funds across top 10 holdings, yield, sector weights and historical returns.
NAV Performance and Flows
Key Data
Compare
XDNA
FBT
| AuM | $15.36 M | $6.91 M |
| Management Fees | 0.39% | 0.15% |
| Exp. ratio | 0.44% | 0.71% |
| Tracking Difference | -1.01% | - |
Historical performance and flows
As of September 8, 2026
| 1M | 3M | YTD | 1Y | 3Y | ||
|---|---|---|---|---|---|---|
| Perf. | XDNA | +9.92% | +33.63% | +50.65% | +72.37% | +82.86% |
FBT | +1.63% | +18.67% | +29.08% | +49.70% | +76.77% | |
| Flows | XDNA | +$3 M | +$5 M | +$6 M | +$6 M | +$6 M |
FBT | +$0 M | +$2 M | +$4 M | +$4 M | +$3 M |
XDNA vs FBT exposure
Countries
XDNA
USA
60.39%
Germany
8.55%
France
7.33%
Other
23.74%
FBT
USA
82.19%
Other
17.81%
Sectors
XDNA
Healthcare
99.82%
FBT
Healthcare
99.86%
As of September 8, 2026
Top 10 Holdings
XDNA
Bayer AG
4.77%
Twist Bioscience Corp.
4.73%
Revolution Medicines, Inc.
4.61%
Moderna, Inc.
4.37%
Incyte Corp.
4.30%
Takeda Pharmaceutical Co., Ltd.
4.19%
Regeneron Pharmaceuticals, Inc.
4.16%
Genmab A/S
4.12%
Vertex Pharmaceuticals, Inc.
3.86%
Merck & Co., Inc.
3.85%
FBT
Halozyme Therapeutics, Inc.
4.31%
Corcept Therapeutics, Inc.
4.08%
Repligen Corp.
3.87%
Regeneron Pharmaceuticals, Inc.
3.85%
BeOne Medicines Ltd.
3.83%
BioNTech SE
3.75%
Natera, Inc.
3.73%
Amgen, Inc.
3.70%
argenx SE
3.66%
NeoGenomics, Inc.
3.63%
Diversification
XDNA
Total weight of top 10 holdings out of 47 total
42.96%
FBT
Total weight of top 10 holdings out of 30 total
38.41%
Characteristics
Compare
XDNA
FBT
| Provider | iShares | First Trust |
| Management | Passively managed | Passively managed |
| Benchmark | NYSE FactSet Global Genomics and Immuno Biopharma NR Index - CAD | NYSE Arca Biotechnology Total Return Index - USD |
| Replication Method | Direct (Physical) | |
| Asset Class | Equity | Equity |
| Dividend Policy | Distributing | Distributing |
| Trailing 12m distribution yield | 0.21% | 0.00% |
| Meets ESG criteria | No | No |
| Inception Date | April 26, 2022 | October 30, 2014 |
Frequently asked questions about XDNA and FBT
Which ETF has performed better year to date: XDNA or FBT?
As of September 8, 2026, XDNA has returned 50.65% year to date, while FBT has returned 29.08%. XDNA is ahead on YTD performance.
Which ETF is larger by assets under management: XDNA or FBT?
As of September 8, 2026, XDNA manages $15.36 M in assets, while FBT manages $6.91 M. XDNA is the larger fund by AUM.
How are XDNA and FBT managed?
XDNA is passively managed by iShares. It tracks the NYSE FactSet Global Genomics and Immuno Biopharma NR Index - CAD benchmark. FBT is passively managed by First Trust. It tracks the NYSE Arca Biotechnology Total Return Index - USD benchmark.
What sectors do XDNA and FBT emphasize?
XDNA is most exposed to Healthcare. FBT is most exposed to Healthcare.
Which ETF is attracting more investor flows: XDNA or FBT?
Year to date, XDNA has seen +$6.43 M in net flows, compared with +$3.89 M for FBT. XDNA has attracted more net investor money so far.
How do the fees of XDNA and FBT compare?
XDNA has an expense ratio of 0.44%, while FBT has an expense ratio of 0.71%.
What are the top holdings of XDNA and FBT?
XDNA's largest holdings include Bayer AG, Twist Bioscience Corp., and Revolution Medicines, Inc.. FBT's top holdings include Halozyme Therapeutics, Inc., Corcept Therapeutics, Inc., and Repligen Corp..
Which ETF is more diversified: XDNA or FBT?
XDNA holds 47 securities, while FBT holds 30. On holdings count, XDNA is the more diversified portfolio.
Recent articles about XDNA and FBT
The ETF Market Canada is brought to you by Cboe in partnership with Trackinsight SA who is providing all the data, analysis and editorial content on this site. Unless explicitly stated as such, any information that you receive is not real-time.
All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
All content on the ETF Market Canada is for your general information use only, Cboe is not responsible for any use of content by you outside this scope. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by Cboe and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.